Simba Gill - 07 Feb 2023 Form 4 Insider Report for Evelo Biosciences, Inc.

Role: President & CEO, Director
Signature: /s/ Dominic V. Capasso, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.
Issuer symbol: EVLO on OTC
Transactions as of: 07 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 09 Feb 2023, 15:38:30 UTC
Previous filing: 14 Sep 2022
Next filing: 10 May 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVLO	Stock Option (Right to Buy)	Award	$0	+1,125,000		$0.000000	1,125,000	07 Feb 2023	Common Stock	1,125,000	$0.9700	Direct	F1
transaction	EVLO	Restricted Stock Units	Award	$0	+375,000		$0.000000	375,000	07 Feb 2023	Common Stock	375,000	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to the reporting person's continued service to the issuer on each such vesting date.
F2	The Restricted Stock Units vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date.